Styrelse — Gabather

På krafman.se hittar du information om Skolling - Krafman AB

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Athera is managed by a core team of senior professionals Follow Athera Biotechnologies AB. Tags. athera 23 athera biotechnologies 22 cardiovascular disease 18 therapeutic antibody 16 Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera reports last patient visit for Phase 2 trial in STEMI patients Press releases • Jul 08, 2020 08:06 CEST. Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera Biotechnologies AB, 556620-6859 är ett aktiebolag i Stockholm som registrerades år 2002 och är verksamt inom Annan naturvetenskaplig och teknisk forskning och utveckling. Athera Biotechnologies AB har haft sitt nuvarande firmanamn sedan 2002-02-18.

Athera biotechnologies ab

Största aktieägare är Industrifonden, Östersjöstiftelsen och Linc AB. Athera har precis avslutat en emission med Sciety. Läkemedelsbolaget Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr där Industrifonden, Östersjöstiftelsen och Sciety-nätverket deltog. Det nya kapitalet ska användas för en klinisk fas 2-studie och bolaget siktar på ett förvärv från en större aktör efter att studien är genomförd. Ansvarig för Business Development på Nanexa sedan 2015, styrelseledamot och Chief Business Officer i Asarina Pharma AB, styrelseledamot i Athera Biotechnologies AB och Bactaviva, VD och styrelseledamot i Isles of Wines AB samt VD och styrelseordförande i Pharmor AB. Athera Biotechnologies AB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). 21 Nov 2016 Athera Biotechnologies AB (Athera) is a biopharmaceutical company that develops targeted anti inflammatory biological candidate drugs and They proposed that Annexin A5 could be developed as a treatment for atherosclerosis.

Senaste: Årsredovisning 2017.

Athera Biotechnologies AB, STOCKHOLM Företaget eniro.se

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat.

Athera Biotechnologies-arkiv - BioStock

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb.

Bolaget registrerat: 2002. Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr aktieägare, däribland Industrifonden, Linc AB och Östersjöstiftelsen. Industrifonden investerar 11 miljoner kronor i det svenska life science-bolaget Athera Biotechnologies, enligt ett pressmeddelande.
Wigartiste reviews

Aktiekapitalet är 8 269 700 kr. Kontaktuppgifter till Athera Biotechnologies AB STOCKHOLM, adress, telefonnummer, se information om företaget. Athera Biotechnologies AB, Stockholm, Sweden Business: Cardiovascular Appointed: Gunnar Olsson as chairman, formerly head of the global cardiovascular and gastrointestinal disease team at AstraZeneca plc ; he replaces Per Sjoberg, who resigned WIR Staff Cardiovascular Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach. , adress mm för Athera Biotechnologies AB. En fullständig upplysning med all information som UC har om bolaget och med en kreditbedömning i form av UC:s unika Riskklass och Riskprognos samt en rekommenderad kreditlimit.

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease Athera is a clinical stage biopharmaceutical company focused on developing targeted In 2005, Karolinska licensed IP covering ANXA5 to Athera Biotechnologies ABa company developing anti-inflammatory therapeutics for cardiovascular diseases based on separate research from Karolinska. Knut PETTERSSON | Cited by 2,060 | of Athera Biotechnologies AB, Solna (ATHERA) | Read 85 publications | Contact Knut PETTERSSON Athera Biotechnologies AB is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD). The company has a proprietary clinical development stage program with the lead candidate, ATH3G10. "Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. The company started development of its lead program in 2008, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden." Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board.
Hudmottagning skovde

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a … Athera Biotechnologies AB Follow Following Location: Sweden. Founded in 2005. Private Company " Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. The company started development of its lead program Athera Biotechnologies AB is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD).

tjänstemannaavtalet byggnads
agarbyte bat
jesus till barnen 2021
anonym e postadress
lacan jacques biografia
libanon wikipedia

Styrelse - Irlab - IRLAB Therapeutics

Our therapeutic antibody ATH3G10 is a first-in-class candidate.

Jag utvidgar schemat: Jag tjänade 30472 SEK på 1 månad

It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit.

20+ million members; 135+ million About Athera Biotechnologies AB (publ) Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD).